Drugs / Florbetazine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06593626 | Nov 2023 → Jun 2025 | — | HTA Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Florbetazine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06593626 ↗ |
| Modality | Diagnostic / imaging agent | “the AD amyloid tracer [18F]Florbetazine” PMID 41518400 ↗ Jan 2026 |